Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
about
The use of modeling tools to drive efficient oral product designPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationHow to report and discuss ADME data in medicinal chemistry publications: in vitro data or in vivo extrapolations?Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variabilityPreclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.An evaluation of the latest in vitro tools for drug metabolism studies.Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Bioactivation of loxoprofen to a pharmacologically active metabolite and its disposition kinetics in human skin.Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates.Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.Incorporating Human Dosimetry and Exposure Information with High-Throughput Screening Data in Chemical Toxicity AssessmentHuman tissue-engineered skeletal muscle: a novel 3D in vitro model for drug disposition and toxicity after intramuscular injectionStatistical relationship between metabolic decomposition and chemical uptake predicts bioconcentration factor data for diverse chemical exposures
P2860
Q26824320-534BB433-B926-4D55-A0DD-160161569084Q28088352-BBCEDC5D-9A84-4D30-B6EF-FB663187228BQ30920065-9EE445D0-C003-4472-B0C8-89CE85FD1C12Q34574831-5BE77349-F130-408F-B347-C5676B529B9EQ36751935-7CBF52D8-57BF-45F9-99EB-CCB53E2EF479Q36910606-328D7CB7-1257-47E4-AA8B-FCB7372F061DQ37559546-EE3147F5-12AA-46BF-B56F-034F6A196880Q37600381-1E004FDE-7916-49A1-9512-1E69E0CB00F5Q38014312-9E7D9156-7092-4979-AB6F-5BFB71C2498FQ38087695-41DBF3A1-DF57-4EAE-9F67-C4DC15BEAA1CQ38160881-59C060D4-C120-4D24-A63C-EAA9A15C0066Q38351385-1C55676E-9F51-4A32-A328-5E6E7495E456Q38621024-C083CBE6-D8FB-4E5F-8697-3C233EA20C1EQ41768726-7D7B5B04-C6B9-408E-A7BD-5CA7A1AFD4F9Q45243894-D52B4573-B211-4E09-B905-A9E8FC73FF58Q47592224-82F3BA17-4FB0-4D81-80AE-702EB31A81D6Q50949191-0F8BABA3-7D19-4114-B431-FE8BC53D7D69Q51051365-1403CB2C-9734-4C43-88C1-D17D127BC1F4Q51825953-6097864C-4491-4674-B4E3-A38BB96C4FC6Q54316808-B83EEB31-4FC3-4A2A-891C-8F77863FB3B6Q57543212-7F759A21-F7CA-4D30-88BA-FA4C032711FBQ58778324-BB74E758-E893-4523-B56E-5C0DFCB4212AQ58797606-E25A5326-AE10-4240-9E34-03F872173AD8
P2860
Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Application of IVIVE and PBPK ...... phase with four case studies.
@en
Application of IVIVE and PBPK ...... phase with four case studies.
@nl
type
label
Application of IVIVE and PBPK ...... phase with four case studies.
@en
Application of IVIVE and PBPK ...... phase with four case studies.
@nl
prefLabel
Application of IVIVE and PBPK ...... phase with four case studies.
@en
Application of IVIVE and PBPK ...... phase with four case studies.
@nl
P2093
P2860
P356
P1476
Application of IVIVE and PBPK ...... phase with four case studies.
@en
P2093
Jane R Kenny
Sophie Mukadam
Vikram Malhi
P2860
P356
10.1002/BDD.1769
P577
2012-01-24T00:00:00Z